Literature DB >> 582438

Successful outcome of ergocryptine-induced pregnancies in twenty-one women with prolactin-secreting pituitary adenomas.

B Corenblum.   

Abstract

The natural history of prolactin-secreting adenomas is not known. For this reason, optimal therapy for women harboring these adenomas who desire to conceive is also unknown. Argument can be found to favor surgical excision, radiation therapy, prolactin-suppressing chemotherapy, and clinical observation. In a large series of women with prolactin-secreting pituitary adenomas, 21 have conceived and delivered healthy infants, all of whom had ergocryptine-induced prolactin suppression as the sole form of therapy. Endocrinologic, neurologic, biochemical, and radiologic assessment failed to demonstrate any obvious growth of the pituitary adenoma, except for slight enlargement of the sella turcica in one patient who delivered twins. The failure to demonstrate any worsening of the clinical state may reflect the fact that no large tumors were included in this series, only small but definite microadenomas found on sellar tomography. All of the various modalities of therapy must be considered with each patient, but this series suggests that ergocryptine treatment with careful clinical follow-up is relatively safe in patients with small pituitary tumors.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 582438     DOI: 10.1016/s0015-0282(16)44177-4

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  5 in total

Review 1.  Management of endocrine disorders in pregnancy. Part II. Pituitary, ovarian and adrenal disease.

Authors:  Z M van der Spuy; H S Jacobs
Journal:  Postgrad Med J       Date:  1984-05       Impact factor: 2.401

2.  The management of prolactin-secreting pituitary tumors.

Authors:  S R George; G N Burrow
Journal:  J Endocrinol Invest       Date:  1981 Oct-Dec       Impact factor: 4.256

3.  Partial remission of hyperprolactinemic amenorrhea after bromocriptine-induced pregnancy.

Authors:  C Campagnoli; L Belforte; F Massara; C Peris; G M Molinatti
Journal:  J Endocrinol Invest       Date:  1981 Jan-Mar       Impact factor: 4.256

4.  Bromocriptine-induced regression of a suprasellar extending prolactinoma during pregnancy.

Authors:  T Bergh; S J Nillius; P Enoksson; L Wide
Journal:  J Endocrinol Invest       Date:  1984-04       Impact factor: 4.256

Review 5.  Diagnosis and management of prolactinomas.

Authors:  J R Dollar; R E Blackwell
Journal:  Cancer Metastasis Rev       Date:  1986       Impact factor: 9.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.